At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,019 enrolled
Drug / intervention
Rimegepantdrug
Likely dose
Rimegepant 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Rimegepant for Migraine, With or Without Aura. Completed, enrolled 3,019 participants across 98 sites.
Detailed Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedAug 30, 2017
Enrollment StartAug 30, 2017
Primary CompletionJul 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.8 years ago
Interventions
Rimegepantdrug
75 mg oral tablet